This company has been marked as potentially delisted and may not be actively trading.

GlycoMimetics (GLYC) Competitors

GLYC vs. TLPH, ATHE, ATRA, SNSE, and RNXT

Should you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include Talphera (TLPH), Alterity Therapeutics (ATHE), Atara Biotherapeutics (ATRA), Sensei Biotherapeutics (SNSE), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical products" industry.

How does GlycoMimetics compare to Talphera?

GlycoMimetics (NASDAQ:GLYC) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

75.2% of GlycoMimetics shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 8.7% of GlycoMimetics shares are owned by insiders. Comparatively, 5.7% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Talphera has higher revenue and earnings than GlycoMimetics. Talphera is trading at a lower price-to-earnings ratio than GlycoMimetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlycoMimetics	$10K	1,013.15	-$37.88M	-$0.46	N/A
Talphera	$30K	1,563.40	-$14.29M	-$0.37	N/A

In the previous week, Talphera had 1 more articles in the media than GlycoMimetics. MarketBeat recorded 1 mentions for Talphera and 0 mentions for GlycoMimetics. GlycoMimetics' average media sentiment score of 0.00 equaled Talphera'saverage media sentiment score.

Company	Overall Sentiment
GlycoMimetics	Neutral
Talphera	Neutral

GlycoMimetics has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Talphera has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Talphera's return on equity of -118.61% beat GlycoMimetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlycoMimetics	N/A	-230.74%	-177.39%
Talphera	N/A	-118.61%	-62.47%

Talphera has a consensus price target of $3.00, indicating a potential upside of 231.97%. Given Talphera's stronger consensus rating and higher possible upside, analysts clearly believe Talphera is more favorable than GlycoMimetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlycoMimetics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Talphera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Talphera beats GlycoMimetics on 10 of the 14 factors compared between the two stocks.

How does GlycoMimetics compare to Alterity Therapeutics?

GlycoMimetics (NASDAQ:GLYC) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Alterity Therapeutics has lower revenue, but higher earnings than GlycoMimetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlycoMimetics	$10K	1,013.15	-$37.88M	-$0.46	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlycoMimetics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Alterity Therapeutics had 1 more articles in the media than GlycoMimetics. MarketBeat recorded 1 mentions for Alterity Therapeutics and 0 mentions for GlycoMimetics. GlycoMimetics' average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score.

Company	Overall Sentiment
GlycoMimetics	Neutral
Alterity Therapeutics	Neutral

Alterity Therapeutics' return on equity of 0.00% beat GlycoMimetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlycoMimetics	N/A	-230.74%	-177.39%
Alterity Therapeutics	N/A	N/A	N/A

75.2% of GlycoMimetics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 8.7% of GlycoMimetics shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GlycoMimetics has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500.

Summary

Alterity Therapeutics beats GlycoMimetics on 7 of the 10 factors compared between the two stocks.

How does GlycoMimetics compare to Atara Biotherapeutics?

GlycoMimetics (NASDAQ:GLYC) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

75.2% of GlycoMimetics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 8.7% of GlycoMimetics shares are held by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Atara Biotherapeutics has higher revenue and earnings than GlycoMimetics. GlycoMimetics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlycoMimetics	$10K	1,013.15	-$37.88M	-$0.46	N/A
Atara Biotherapeutics	$120.77M	0.59	$32.69M	$3.12	2.67

Atara Biotherapeutics has a consensus price target of $9.50, indicating a potential upside of 13.91%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than GlycoMimetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlycoMimetics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Atara Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Atara Biotherapeutics had 25 more articles in the media than GlycoMimetics. MarketBeat recorded 25 mentions for Atara Biotherapeutics and 0 mentions for GlycoMimetics. Atara Biotherapeutics' average media sentiment score of 0.03 beat GlycoMimetics' score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
GlycoMimetics	Neutral
Atara Biotherapeutics	Neutral

GlycoMimetics has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500.

Atara Biotherapeutics has a net margin of 27.07% compared to GlycoMimetics' net margin of 0.00%. Atara Biotherapeutics' return on equity of -79.12% beat GlycoMimetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlycoMimetics	N/A	-230.74%	-177.39%
Atara Biotherapeutics	27.07%	-79.12%	87.55%

Summary

Atara Biotherapeutics beats GlycoMimetics on 13 of the 16 factors compared between the two stocks.

How does GlycoMimetics compare to Sensei Biotherapeutics?

GlycoMimetics (NASDAQ:GLYC) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

Sensei Biotherapeutics' return on equity of -83.59% beat GlycoMimetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlycoMimetics	N/A	-230.74%	-177.39%
Sensei Biotherapeutics	N/A	-83.59%	-69.97%

75.2% of GlycoMimetics shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 8.7% of GlycoMimetics shares are held by company insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sensei Biotherapeutics has a consensus target price of $40.00, indicating a potential upside of 70.94%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than GlycoMimetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlycoMimetics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

GlycoMimetics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500.

Sensei Biotherapeutics has lower revenue, but higher earnings than GlycoMimetics. Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than GlycoMimetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlycoMimetics	$10K	1,013.15	-$37.88M	-$0.46	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$16.67	N/A

In the previous week, Sensei Biotherapeutics had 2 more articles in the media than GlycoMimetics. MarketBeat recorded 2 mentions for Sensei Biotherapeutics and 0 mentions for GlycoMimetics. Sensei Biotherapeutics' average media sentiment score of 0.02 beat GlycoMimetics' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
GlycoMimetics	Neutral
Sensei Biotherapeutics	Neutral

Summary

Sensei Biotherapeutics beats GlycoMimetics on 9 of the 14 factors compared between the two stocks.

How does GlycoMimetics compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

RenovoRx has higher revenue and earnings than GlycoMimetics. RenovoRx is trading at a lower price-to-earnings ratio than GlycoMimetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	34.74	-$11.17M	-$0.32	N/A
GlycoMimetics	$10K	1,013.15	-$37.88M	-$0.46	N/A

RenovoRx presently has a consensus target price of $8.25, indicating a potential upside of 855.30%. Given RenovoRx's stronger consensus rating and higher possible upside, equities research analysts clearly believe RenovoRx is more favorable than GlycoMimetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
GlycoMimetics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, RenovoRx had 1 more articles in the media than GlycoMimetics. MarketBeat recorded 1 mentions for RenovoRx and 0 mentions for GlycoMimetics. GlycoMimetics' average media sentiment score of 0.00 beat RenovoRx's score of -0.33 indicating that GlycoMimetics is being referred to more favorably in the news media.

Company	Overall Sentiment
RenovoRx	Neutral
GlycoMimetics	Neutral

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 75.2% of GlycoMimetics shares are owned by institutional investors. 9.1% of RenovoRx shares are owned by insiders. Comparatively, 8.7% of GlycoMimetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

RenovoRx has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, GlycoMimetics has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

GlycoMimetics has a net margin of 0.00% compared to RenovoRx's net margin of -994.48%. RenovoRx's return on equity of -119.77% beat GlycoMimetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-994.48%	-119.77%	-91.25%
GlycoMimetics	N/A	-230.74%	-177.39%

Summary

RenovoRx beats GlycoMimetics on 11 of the 17 factors compared between the two stocks.

Get GlycoMimetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLYC vs. The Competition

Export

Metric	GlycoMimetics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.13M	$904.51M	$6.25B	$12.13B
Dividend Yield	N/A	4.84%	2.78%	5.20%
P/E Ratio	-0.34	1.56	20.88	25.39
Price / Sales	1,013.15	121.19	533.46	78.15
Price / Cash	N/A	20.07	43.29	53.47
Price / Book	1.96	7.71	9.98	6.81
Net Income	-$37.88M	-$5.06M	$3.54B	$332.87M

GlycoMimetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLYC GlycoMimetics	N/A	$0.16 flat	N/A	N/A	$10.13M	$10K	N/A	50	Gap Up
TLPH Talphera	2.1254 of 5 stars	$0.81 +5.8%	N/A	+70.5%	$40.48M	$30K	N/A	19	News Coverage Upcoming Earnings
ATHE Alterity Therapeutics	0.7597 of 5 stars	$4.56 -0.4%	N/A	+18.2%	$40.43M	N/A	N/A	10
ATRA Atara Biotherapeutics	2.3653 of 5 stars	$4.60 -2.7%	$6.00 +30.4%	+36.8%	$39.15M	$120.77M	1.47	330	Trending News Analyst Forecast Gap Down
SNSE Sensei Biotherapeutics	1.6944 of 5 stars	$28.30 -2.8%	$40.00 +41.3%	+203.1%	$39.04M	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLYC) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GlycoMimetics (GLYC) Competitors

GLYC vs. TLPH, ATHE, ATRA, SNSE, and RNXT

How does GlycoMimetics compare to Talphera?

Summary

How does GlycoMimetics compare to Alterity Therapeutics?

Summary

How does GlycoMimetics compare to Atara Biotherapeutics?

Summary

How does GlycoMimetics compare to Sensei Biotherapeutics?

Summary

How does GlycoMimetics compare to RenovoRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLYC vs. The Competition

GlycoMimetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GlycoMimetics (GLYC) Competitors

GLYC vs. TLPH, ATHE, ATRA, SNSE, and RNXT

How does GlycoMimetics compare to Talphera?

Do insiders and institutionals believe in GLYC or TLPH?

Which has stronger valuation & earnings, GLYC or TLPH?

Does the media favor GLYC or TLPH?

Which has more volatility and risk, GLYC or TLPH?

Is GLYC or TLPH more profitable?

Do analysts prefer GLYC or TLPH?

Summary

How does GlycoMimetics compare to Alterity Therapeutics?

Which has stronger valuation & earnings, GLYC or ATHE?

Do analysts prefer GLYC or ATHE?

Does the media favor GLYC or ATHE?

Is GLYC or ATHE more profitable?

Do insiders and institutionals believe in GLYC or ATHE?

Which has more volatility and risk, GLYC or ATHE?

Summary

How does GlycoMimetics compare to Atara Biotherapeutics?

Do insiders & institutionals believe in GLYC or ATRA?

Which has better earnings & valuation, GLYC or ATRA?

Do analysts recommend GLYC or ATRA?

Does the media prefer GLYC or ATRA?

Which has more volatility and risk, GLYC or ATRA?

Is GLYC or ATRA more profitable?

Summary

How does GlycoMimetics compare to Sensei Biotherapeutics?

Is GLYC or SNSE more profitable?

Do insiders & institutionals believe in GLYC or SNSE?

Do analysts rate GLYC or SNSE?

Which has more risk & volatility, GLYC or SNSE?

Which has higher earnings & valuation, GLYC or SNSE?

Does the media prefer GLYC or SNSE?

Summary

How does GlycoMimetics compare to RenovoRx?

Which has better earnings & valuation, RNXT or GLYC?

Do analysts prefer RNXT or GLYC?

Does the media favor RNXT or GLYC?

Do institutionals & insiders have more ownership in RNXT or GLYC?

Which has more risk & volatility, RNXT or GLYC?

Is RNXT or GLYC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLYC vs. The Competition

GlycoMimetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools